Clarivate announces it will sell its Life Sciences & Healthcare segment to Altaris for $600 million, according to company communications and financial coverage. The transaction is described as part of Clarivate’s effort to sharpen its focus on its remaining business areas, including Academia & Government and Intellectual Property. Clarivate says the deal is intended to support its AI-driven “transformative intelligence” strategy for those segments. The company also links the sale to expected improvements in its financial profile, including a better revenue mix, higher Adjusted EBITDA margin, and lower capital intensity. Clarivate indicates it will use proceeds from the sale, though specific allocation details are not fully provided in the excerpts shared. Seeking Alpha reports the company’s share price jumps roughly 16% following the announcement, reflecting market reaction to the planned divestiture. The agreement is presented as a restructuring step that reduces reliance on the sold unit and reallocates resources toward Clarivate’s core segments. The transaction is still subject to customary closing conditions, as is typical for deals of this type.